Merck buys rights to NewLink's experimental Ebola vaccine

November 24, 2014 2:11 PM

2 0

(Reuters) - Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.O) experimental vaccine meant to prevent infection with the Ebola virus.

Large late-stage trials of the product could begin early next year, Merck said.

Also read: Key Obamacare premiums to jump 25 percent next year

Read more

To category page